Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

Journal of the American College of Cardiology

Volumn 37, Issue 2, 2001, Pages 440-444

  Navalkar, Sushant ^a   Parthasarathy, Sampath ^a   Santanam, Nalini ^a   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IRBESARTAN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING;

ADULT; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CORONARY ARTERIOSCLEROSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0035131472     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)01138-4     Document Type: Article

References (29)

1. The pathogenesis of atherosclerosis: A perspective for the 1990s
2. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease
3. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice
4. Pathogenesis of atherosclerosis and its complications: Effects of antihypertensive drugs
5. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: Effects on blood pressure, serum lipids, and coronary heart disease risk
6. The effect of ACE inhibitors on atheroma formation is potentiated by association with a calcium channel blocker. A biochemical and ultrastructural study
7. Review of preclinical data of calcium channel blockers and atherosclerosis
8. Pharmacology of carvedilol: Rationale for use in hypertension, coronary artery disease, and congestive heart failure
9. Angiotensin II and the adrenal
10. 1 receptors in the central control of sympathetic vasomotor function
11. Identification of angiotensin II receptor subtypes
12. Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers
13. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report
14. Nitric oxide and the depressor response to angiotensin blockade in hypertension
15. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease
16. Circulating adhesion molecules and severity of coronary atherosclerosis
17. Inflammatory markers in men with angiographically documented coronary heart disease
18. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis
19. Ultrarapid communications: Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors
20. Angiotensin II sitmulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
21. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis
22. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
23. Superoxide: A two-edged sword
24. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis
25. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-NADPH-oxidase
26. Evidence for a causal role of the rennin-angiotensin system in nitrate tolerance
27. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: No clear relationship with levels of tumor necrosis factor
28. Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis